Synthesis and investigation of conformationally restricted analogues of lavendustin A as cytotoxic inhibitors of tubulin polymerization

Journal of Medicinal Chemistry

Volumn 45, Issue 21, 2002, Pages 4774-4785

  Mu, Fanrong ^a   Lee, Debbie J ^b   Pryor, Donald E ^b   Hamel, Ernest ^b   Cushman, Mark ^a  

^a PURDUE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; LAVENDUSTIN A;

ARTICLE; BROMINATION; CANCER CELL CULTURE; CYTOTOXICITY; HYDROGEN BOND; MICROTUBULE ASSEMBLY; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; BIOPOLYMERS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR CONFORMATION; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0037057549     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0202270     Document Type: Article

References (41)

1. Levitski, A. Protein Tyrosine Kinase Inhibitors as Therapeutic Agents. Top. Curr. Chem. 2001, 211, 1-15.
2. Traxler, P.; Furet, R. Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors. Pharmacol. Ther. 1999, 82, 195-206.
3. Hamby, J. M.; Showalter, H. D. Small Molecule Inhibitors of Tumor-Promoted Angiogenesis, Including Protein Tyrosine Kinase Inhibitors. Pharmacol. Ther. 1999, 82, 169-193.
4. Al-Obeidi, F. A.; Lam, K. S. Development of Inhibitors for Protein Tyrosine Kinases. Oncogene 2000, 19, 5690-5701.
5. Traxler, P. Tyrosine Kinase Inhibitors in Cancer Treatment (Part II). Exp. Opin. Ther. Pat. 1998, 8, 1599-1625.
6. Buchdunger, E.; Cioffi, C. L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B. J.; Lydon, N. B. Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor. Receptors J. Pharmacol. Exp. Ther. 2000, 295, 139-145.
7. Bange, J.; Zwick, E.; Ullrich, A. Molecular Targets for Breast Cancer Therapy and Prevention. Nat. Med. 2001, 7, 548-525.
8. Lu, Y.; Zi, X.; Zhao, Y.; Mascarenhas, D.; Pollack, M. Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93, 1852-1857.
9. Onoda, T.; Iinuma, H.; Sasaki, Y.; Hamada, M.; Isshiki, K.; Naganawa, H.; Takeuchi, T. Isolation of a Novel Tyrosine Kinase Inhibitor, Lavendustin A, from Streptomyces griseolavendus. J. Nat. Prod. 1989, 52, 1252-1257.
10. Hsu, C.-Y. J.; Persons, P. E.; Spada, A. P.; Bednar, R. A.; Levitzki, A.; Zilberstein, A. Kinetic Analysis of the Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by Lavendustin A and Its Analogue. J. Biol. Chem. 1991, 266, 21105-21112.
11. Imoto, M.; Sujikai, I.; Ui, H.; Umezawa, K. Involvement of Tyrosine Kinase in Growth Factor-Induced Phospholipase C Activation in NIH3T3 Cells. Biochim. Biophys. Acta 1993, 1166, 188-192.
12. Smyth, M. S.; Stefanova, I.; Hartman, F.; Horad, I. D.; Osherov, N.; Levitzki, A.; Burke, T. R. J. Non-Amine Based Analogues of Lavendustin A as Protein-Tyrosine Kinase Inhibitors. J. Med. Chem. 1993, 36, 3010-3014.
13. Smyth, M. S.; Stefanova, I.; Horak, I. D.; Burke, T. R., Jr. Hydroxylated 2-(5′-Salicyl)naphthalenes as Protein-Tyrosine Kinase Inhibitors. J. Med. Chem. 1993, 36, 3015-3020.
14. Chen, H.; Boiziau, J.; Parker, F.; Maroun, R.; Tocque, B.; Roques, B. P.; Garbay-Jaureguiberry, C. Synthesis and Structure-Activity Studies of a Series of [(Hydroxybenzyl)amino]salicylates as Inhibitors of EGF Receptor-Associated Tyrosine Kinase Activity. J. Med. Chem. 1993, 36, 4094-4098.
15. Chen, H.; Boiziau, J.; Parker, F.; Mailliet, P.; Commerçon, A.; Tocque, B.; Le Pecq, J.-B.; Roques, B.-P.; Garbay, C. Structure-Activity Relationships in a Series of 5-[2,5-Dihydroxybenzyl)-amino]salicylate Inhibitors of EGF-Receptor-Associated Tyrosine Kinase: Importance of Additional Hydrophobic Aromatic Interactions. J. Med. Chem. 1994, 37, 845-859.
16. F527 In Vitro and in Intact Cells. Eur. J. Pharmacol. 1994, 269, 1-8.
17. Nussbaumer, P.; Winiski, A. P.; Cammisuli, S.; Hiestand, P.; Weckbecker, G.; Stütz, A. Novel Antiproliferative Agents Derived from Lavendustin A. J. Med. Chem. 1994, 37, 4079-4084.
18. Liu, T.; Shirai, R.; Matsui, T.; Umezawa, K.; Iwasaki, S. Synthesis and Biological Activity of 5-[2,5-Dihydroxybenzyl)-amino] salicylic Acid Analogues as Inhibitors of EGF Receptor-Associated Protein Tyrosine Kinase. Bioorg. Med. Chem. Lett. 1997, 7, 365-368.
19. Green, J. Solid-Phase Synthesis of Lavendustin A and Analogues. J. Org. Chem. 1995, 60, 4287-4290.
20. Devraj, R.; Cushman, M. A Versatile Solid-Phase Synthesis of Lavendustin A and Certain Biologically Active Analogues. J. Org. Chem. 1996, 61, 9368-9373.
21. Mu, F.; Coffing, S. L.; Riese, D. J. I.; Geahlen, R. L.; Verdier-Pinnard, P.; Hamel, E.; Johnson, J.; Cushman, M. Design, Synthesis, and Biological Evaluation of a Series of Lavendustin A Analogues That Inhibit EGFR and Syk Tyrosine Kinases, as Well as Tubulin Polymerization. J. Med. Chem. 2001, 44, 441-452.
22. Onoda, T.; Isshiki, K.; Takeuchi, T.; Tatsuta, K.; Umezawa, K. Inhibition of Tyrosine Kinase and Epiderman Growth Factor Internalization by Lavendustin A Methyl Ester in Cultured A431 Cells. Drugs Exptl. Clin. Res. 1990, 16, 249-253.
23. Schweitzer, B. A.; Kool, E. Aromatic Nonpolar Nucleosides as Hydrophobic Isosteres of Pyrimidine and Purine Nucleosides. J. Org. Chem. 1994, 59, 7238-7242.
24. Riese, D. J. I.; van Raaij, T. M.; Plowman, G. D.; Andrews, G. C.; Stern, D. F. The Cellular Response to Neuregulins is Governed by Complex Interactions of the ErbB Receptor Family. Mol. Cell. Biol. 1995, 15, 5770-5776.
25. Paull, K. D.; Hamel, E.; Malspeis, L. Prediction of Biochemical Mechanism of Action from the In Vitro Antitumor Screen of The National Cancer Institute; American Chemical Society: Washington, DC, 1995
26. Zaleska, B.; Lis, S. An Efficient and Novel Synthesis of 1,3-Benzoxazine-2,4-dione and Its Derivatives. Pharmazie 1995, 50, 150-151.
27. Stenseth, R. E.; Baker, J. W.; Roman, D. P. Substituted 3-Phenyl-1,3-benzoxazine-2,4-diones and Their Bacteriostatic Activity. J. Med. Chem. 1963, 6, 212-213.
28. Cullis, C. F.; Ladbury, J. W. Kinetic Studies of the Oxidation of Aromatic Compounds by Potassium Permanganate. Part II. Substituted Toluenes. J. Chem. Soc. 1955, 1407-1410.
29. Askam, V.; Deeks, R. H. L. Oxidation and Claisen Condensation Products of 3-Nitro-o-xylene. J. Chem. Soc. 1969, 1935-1936.
30. Visentin, S.; Amiel, P.; Fruttero, R.; Boschi, D.; Roussel, C.; Giusta, L.; Carbone, E.; Gasco, A. Synthesis and Voltage-Clamp Studies of Methyl 1,4-Dihydro-2,6-dimethyl-5-nitro-4-(benzofurazanyl)pyridine-3-carboxylate. J. Med. Chem. 1999, 42, 1422-1427.
31. 3CN. J. Org. Chem. 1997, 62, 4504-4506.
32. Sonogashira, K.; Tohda, Y.; Hagihara, N. A Convenient Synthesis of Acetylenes: Catalytic Substitution of Acetylenic Hydrogen with Bromoalkenes, Iodoarenes, and Bromopyridines. Tetrahedron Lett. 1975, 4467-4470.
33. 3: A Versatile Catalyst for Sonogashira Reactions of Aryl Bromides at Room Temperature Org. Lett. 2000, 2, 1729-1731.
34. Bellamy, F. D.; Ou, K. Selective Reduction of Aromatic Nitro Compounds with Stannous Chloride in Non Acidic Medium. Tetrahedron Lett. 1984, 25, 839-842.
35. Kikukawa, K.; Umekawa, H.; Wada, F.; Matsuda, T. Regioselective Hydrostannation of Terminal Acetylenes Under Transition Metal Catalysis. Chem Lett. 1988, 881-884.
36. Ichinose, Y.; Oda, H.; Oshima, K.; Utimoto, K. Palladium Catalyzed Hydrostannylation and Hydrogermylation of Acetylenes. Bull. Chem. Soc. Jpn. 1987, 60, 3468-3470.
37. Hibino, J.; Matsubara, S.; Morizawa, Y.; Oshima, K.; Nozaki, H. Regioselective Stannylmetalation of Acetylenes in the Presence of Transition-Metal Catalysis. Tetrahedron Lett. 1984, 25, 2151-2154.
38. Zhang, H. X.; Guibé, F.; Balavoine, G. Palladium- and Molybdenum-Catalyzed Hydrostannation of Alkynes. A Novel Access to Regio- and Stereodefined Vinylstannanes. J. Org. Chem. 1990, 55, 1857-1867.
39. c-src. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 892-896.
40. Boden, C. D. J.; Pattenden, G.; Ye, T. Palladium-Catalyzed Hydrostannylations of 1-Bromoalkynes, a Practical Synthesis of (E)-1-Stannylalk-1-enes. J. Chem. Soc., Perkin Trans. 1 1996, 2417-2419.
41. Boyd, M. R.; Paull, K. D. Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev. Res. 1995, 34, 91-109.